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Abstract
The cancer stem cell hypothesis, that a small population of tumour cells are responsible for
tumorigenesis and cancer progression, is becoming widely accepted and recent evidence
has suggested a prognostic and predictive role for such cells. Intra-tumour heterogeneity,
the diversity of the cancer cell population within the tumour of an individual patient, is related
to cancer stem cells and is also considered a potential prognostic indicator in oncology. The
measurement of cancer stem cell abundance and intra-tumour heterogeneity in a clinically
relevant manner however, currently presents a challenge. Here we propose signalling en-
tropy, a measure of signalling pathway promiscuity derived from a sample’s genome-wide
gene expression profile, as an estimate of the stemness of a tumour sample. By considering
over 500 mixtures of diverse cellular expression profiles, we reveal that signalling entropy
also associates with intra-tumour heterogeneity. By analysing 3668 breast cancer and 1692
lung adenocarcinoma samples, we further demonstrate that signalling entropy correlates
negatively with survival, outperforming leading clinical gene expression based prognostic
tools. Signalling entropy is found to be a general prognostic measure, valid in different
breast cancer clinical subgroups, as well as within stage I lung adenocarcinoma. We find
that its prognostic power is driven by genes involved in cancer stem cells and treatment re-
sistance. In summary, by approximating both stemness and intra-tumour heterogeneity, sig-
nalling entropy provides a powerful prognostic measure across different epithelial cancers.
Author Summary
The Cancer Stem Cell (CSC) hypothesis, the idea that a small population of tumour cells
have the capacity to seed and grow the tumour, and intra-tumour heterogeneity, the diver-
sity of the cancer cell population within the tumour of an individual patient, have long
been considered the basis of potential prognostic indicators in oncology. The identification
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preparation of the manuscript.of CSC based expression signatures and the measurement of intra-tumour heterogeneity,
for an assessment of prognostic power in a clinically relevant manner, however, currently
presents a challenge. Most proposed methodologies require the collection of new data sets
and thus are limited in sample size, making them difficult to validate. Here we consider
signalling entropy, a measure of signalling pathway promiscuity, as a means of quantifying
the stemness and heterogeneity of any given cancer sample, applicable to publicly available
data sets. By considering over 5300 primary tumour samples from both breast and lung
cancer patients, we here demonstrate that signalling entropy provides a more robust and
general prognostic measure than other leading clinical prognostic indicators.
Introduction
Over recent years considerable evidence has arisen supporting the hypothesis that some can-
cers are hierarchically organised, akin to the organisation of healthy cells, with a small popula-
tion of Cancer Stem Cells (CSCs) driving a heterogeneous, hierarchical structure [1, 2]. The
abundance of CSCs is considered likely to be of prognostic value as well as a source of intra-tu-
mour heterogeneity, a feature that has long been considered of possible prognostic value in on-
cology [3–6]. Although putative CSCs have been identified by surface marker expression for
several malignancies, isolated, and demonstrated to be chemotherapeutic resistant [7–11], it re-
mains a significant challenge to obtain a prognostic measure of their abundance from tumour
bulk gene expression profiles across multiple malignancies. Embryonic Stem (ES) cell gene ex-
pression signatures are clear candidates for such a measure and indeed have been demonstrat-
ed to be prognostic in breast and lung cancer [12–15]. Their overall prognostic significance
seems limited, however, and they are unable to discriminate CSCs from the tumour bulk [12,
16]. The clinical assessment of intra-tumour heterogeneity also poses a significant challenge,
with current experimental approaches requiring multiple biopsies per tumour leaving them se-
verely limited in sample size [17–19]. We posited that an expression based measure of signal-
ling promiscuity may quantify the stemness of a tumour in a manner which is related to intra-
tumour heterogeneity, and thus provide us with an improved prognostic model.
Here we explore this hypothesis, using an in-silico approach. Specifically, we consider signal-
ling entropy which is computed from the integration of a sample’s genome-wide gene expres-
sion profile with an interactome, and provides an overall measure of the signalling promiscuity
in the sample [16]. We note that the term signalling entropy was chosen, as opposed to alterna-
tives such as interactome/network entropy, to emphasise the fact that our measure quantifies
network traffic (signalling) as opposed to network topology. Importantly, as shown by us previ-
ously, signalling entropy correlates with stemness and differentiation potential within distinct
cellular developmental lineages [16]. Indeed, we showed that human embryonic stem cells and
induced pluripotent stem cells exhibited the highest levels of signalling entropy, with adult
stem cells (e.g. hematopoietic stem cells) showing significantly lower values, and terminally dif-
ferentiated cells exhibiting the lowest entropy values within a lineage [16]. These results were
derived mostly from cell-lines, which are characterised by relatively homogeneous cell popula-
tions, and were further validated in time-course differentiation experiments [16]. Importantly,
we also demonstrated that cancerous tissue displays a higher signalling entropy than its healthy
counterpart [16, 20], with CSCs showing higher values than the tumour bulk [16]. Thus, signal-
ling entropy provides an approximation of the stemness of a cellular sample.
In addition to quantifying stemness of the signalling regime of a homogeneous cell popula-
tion, signalling entropy, if computed over a heterogeneous cell population, should also quantify
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that no competing interests exist.the inter-cellular diversity in pathway activation. To investigate this we performed an analytical
investigation of signalling entropy, coupled with empirical validation. We derived a sufficient
condition on the expression profiles of homogeneous cell populations for signalling entropy to
be a measure of intra-sample heterogeneity on average. We subsequently verified that this con-
dition is satisfied by considering 33 distinct adult tissue expression profiles corresponding to
528 pairwise mixtures. Thus, we show that signalling entropy is a good candidate for a correlate
of intra-sample heterogeneity.
Importantly, because signalling entropy can be computed from a bulk tumour gene expres-
sion profile, it allows us to assess the prognostic significance of our measure in large numbers
of clinical specimens. We here compute signalling entropy for a total of 5360 tumour samples,
focusing on two highly heterogeneous cancers, non-small cell lung cancer (NSCLC) and breast
cancer, which constitute the two leading causes of cancer death world-wide [21]. Survival rates
for early stage NSCLC are particularly poor [21, 22], and identification of prognostic and pre-
dictive biomarkers within the stage I stratum is considered a high priority [23]. In breast can-
cer, the power of gene expression based prognostic indicators, such as OncotypeDX and
MammaPrint [24, 25], is highly subtype dependent [26, 27] and a clinical breast cancer prog-
nostic signature, which is independent of estrogen receptor (ER) status is lacking. Most impor-
tantly, current gene expression based prognostic indicators ignore CSC contributions and
intra-tumour heterogeneity [17]. Thus, signalling entropy, a measure of both cell anaplasia and
intra-tumour heterogeneity, may form the basis of a general and more robust prognostic indi-
cator. By examining gene expression profiles of over 3500 primary breast cancers and 1300
lung adenocarcinomas, we here demonstrate that signalling entropy is prognostic in breast
cancer, regardless of ER status, and in lung adenocarcinomas, within the stage I stratum.
Results
Rationale of signalling entropy as a prognostic measure
Signalling entropy is derived from the integration of a sample’s gene expression profile with a
human protein interactome, and provides a rough proxy for the overall level of signalling pro-
miscuity in the sample. Briefly, we employ the mass-action principle to derive, for each sample,
a stochastic matrix pij, describing the interaction probability of the proteins encoded by genes i
and j in the given sample. The signalling entropy is then computed as the normalised entropy
rate of the Markov chain described by pij. This entropy rate gives a steady state measure of the
disorder (or promiscuity) in signalling information flow over the network in the given sample
(Materials and Methods).
As shown by us previously, stem cells have a high signalling entropy which decreases during
differentiation, a result not forthcoming using other molecular entropy measures [16, 28]. Im-
portantly, we also demonstrated that signalling entropy is elevated in CSCs as compared to the
tumour bulk [16]. Thus, given a homogeneous cell population, a high signalling entropy sug-
gests that signalling within each cell is very promiscuous and that the cells may therefore have
a plastic stem cell like phenotype. However, a heterogeneous sample, consisting of cells with
distinct, though not necessarily promiscuous signalling regimes, should also on average display
a high signalling entropy, suggesting that signalling entropy may associate with intra-tumour
heterogeneity (Fig. 1A).
To investigate whether signalling entropy associates with intra-sample heterogeneity, we
considered our measure evaluated for three theoretical samples: namely two homogeneous
samples consisting only of cell type x or y respectively, and a third heterogeneous sample con-
sisting of a 50:50 mixture of cell types x and y. It is clear that if cell type x has an expression pro-
file that maximises signalling entropy and cell type y does not, then the signalling entropy of
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Fig 1. Rationale behind signalling entropy as a prognostic factor in cancer. A) A high signalling entropy of a tumour sample indicates a promiscuous,
stem cell like intra-cellular signalling regime and a heterogeneous cancer cell population. The consequence of a high entropy is thus a tumour with a plastic
phenotype, capable of activating diverse pathways in response to treatment. High signalling entropy tumours are thus likely to result in higher patient
mortality. B) Signalling entropy (denoted SR/max SR) computed for 528 distinct pairwise mixtures of 33 homogeneous tissue samples reveals that our
measure is super-additive and hence will be raised, on average, in mixed samples compared to homogeneous samples. C) Signalling entropy is raised on
average in mixed samples as compared to homogeneous samples, considering the same 33 homogeneous tissue samples as Fig. 1B. The p-value
corresponds to a two tailed paired Wilcoxon signed rank test, and reveals that signalling entropy is significantly elevated in the admixed cell populations
on average.
doi:10.1371/journal.pcbi.1004115.g001
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tinct expression profiles, corresponding to the existence of non-overlapping active pathways
between cell type pairs [29], we posited that the signalling entropy of a mixed sample may be
higher than that of a homogeneous sample on average.
By appealing to detailed balance we examined a closed form expression for signalling entro-
py. It is a consequence of simple algebra that if signalling entropy is super-additive over the set
of biologically admissible expression profiles (i.e., Signalling Entropy
xþy
2
  
>
1
2 Signalling En-
tropy ðxÞþ
1
2 Signalling Entropy(y)) then signalling entropy will on average be elevated in
mixed samples as opposed to homogeneous samples (Materials and Methods, S1 Text, S8 Fig,
S9 Fig, S10 Fig and S11 Fig). We thus derived a condition for point-wise super-additivity of our
measure and then considered a data set of gene expression profiles for 33 distinct adult tissues,
representing 528 possible pairwise mixtures [29]. For every possible mixture the derived condi-
tion for super-additivity was satisfied (Fig. 1B). Whence the signalling entropies of the mixed
samples was significantly higher than that of homogeneous samples on average (Fig. 1C). This
provides strong evidence that signalling entropy is a correlate of intra-sample heterogeneity.
Thus, signalling entropy associates with tumour stemness in a manner associated with CSC
abundance and intra-tumour heterogeneity, making our measure a good candidate for an im-
proved prognostic indicator.
Signalling entropy is prognostic in the major subtypes of breast cancer
In order to assess the prognostic significance of signalling entropy in breast cancer, we first
computed its value for each microarray sample of the Molecular Taxonomy of Breast Cancer
International Research Consortium dataset (METABRIC) [30], a total of 1980 samples divided
into a discovery and validation sets of equal proportion. This data set profiles a large number
of clinical variables and thus is a suitable platform to examine the clinical associations of our
measure. Using outcome first as a binary phenotype, we observed that patients who died of
breast cancer had a higher signalling entropy than patients who were alive at last follow up, a
result which was seen in both METABRIC subsets (p < 1e − 7). Using a Cox proportional haz-
ards model, on 5 year censored survival data, we ascertained that high signalling entropy is as-
sociated with increased risk of death in breast cancer (c-index = 0.6, p < 1.1e − 6). Stratifying
patients into 3 groups, representing the 3 tertiles of the signalling entropy distribution, revealed
that tumours with a high entropy exhibited a doubling of the hazard rate compared to low
entropy tumours.
Signalling entropy was found to be associated with tumour grade and ER status, however,
its prognostic power was independent of these variables, as well as of stage, p53 status, tumour
size and lymph node status (S1 Text, S1 Fig & S2 Fig). In addition, signalling entropy was also
found to be independent of a prognostic ES cell signature described by Ben-Porath el al.[ 12]
and the prognostic grade signature described by Sotiriou et al.[ 31]( S1 Text, S1 Fig & S2 Fig).
Signalling entropy was significantly prognostic within each tumour grade strata; notably it was
prognostic within the grade 2 stratum in both METABRIC data sets (p < 0.036), an important
result given the difficulty in deciding treatment courses in this intermediate prognosis group
[31]. The fact that signalling entropy is prognostic independently of all other measures of cell
anaplasia, suggests that our measure may be capturing more than just the stemness of a tumour
sample, and that intra-tumour heterogeneity may be contributing to its prognostic power.
A recent study by Venet et al. described prognostic associations for a number of random
gene expression signatures in breast cancer [32]. To ascertain whether random effects may be
driving our findings, we evaluated the prognostic associations of the three random gene
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discovery and validation METABRIC data sets and that its prognostic power was determined
by ER status (S3 Fig). To further assess the impact of random effects and the importance of our
network, we randomised the gene expression profiles of the METABRIC data sets over the net-
work. Performing 5 randomisations and recomputing signalling entropy for the 1980 samples
in both METABRIC data sets, revealed that randomised signalling entropy did not display ro-
bust prognostic associations independently of ER status. We are therefore confident that the
prognostic power of signalling entropy is not driven by random effects.
To further validate the prognostic impact of signalling entropy we considered eight further
independent breast cancer data sets. All these datasets described both ER positive and negative
tumours with accompanying clinical outcome, profiled on either Affymetrix or Illummina plat-
forms and totalling 1688 samples [33–40], (S1 Table). Meta-analysis revealed that signalling
entropy is prognostic across both ER positive and ER negative samples (ER positive: c-index =
0.63, 95% CI = (0.604, 0.657), p = 8.5e − 15, ER negative: c-index = 0.57, 95% CI = (0.538,
0.602), p = 0.032, Fig. 2A). Five of the additional eight data sets also described histological tu-
mour grade for each sample, allowing us to further confirm that signalling entropy is prognos-
tic within the grade 2 stratum (c-index = 0.63, 95% CI = (0.581, 0.675), p = 1.05e − 6, Fig. 2A).
These results are in contrast to the performance of MammaPrint, a microarray based breast
cancer prognostic signature currently being assessed in the MINDACT trial [41]. In a meta-
analysis over the 10 breast cancer validation sets we found that unlike signalling entropy Mam-
maPrint was not significantly prognostic over ER negative samples (Fig. 2B).
Another popular breast cancer prognostic assay in clinical trials is OncotypeDX, which uses
RT-PCR to quantify the expression of genes associated with survival [25]. Due to differences in
the normalisation between RT-PCR and microarrays, a direct comparison between our mea-
sure and OncotypeDX is difficult to perform. Moreover, not all the genes required for comput-
ing the OncotypeDX recurrence score were present in all the array platforms considered.
However, using a microarray version of OncotypeDX, we found that it performed comparably
to signalling entropy across both ER positive (signalling entropy vs. OncotypeDX: p = 0.13)
and ER negative samples (signalling entropy vs. OncotypeDX: p = 0.7, S4 Fig).
Thus signalling entropy is prognostic in the two major clinical subtypes of breast cancer and
hence is a more robust prognostic indicator than MammaPrint.
Signalling entropy is prognostic in stage I lung adenocarcinoma
We next investigated the prognostic power of our measure in lung adenocarcinoma. To evalu-
ate the clinical associations of our measure we first computed signalling entropy for each mi-
croarray sample in The Director’s Challenge dataset profiling 398 tumours [42], and for the
455 lung adenocarcinoma RNA-seq tumour samples downloaded from The Cancer Genome
Atlas (TCGA) database (http://cancergenome.nih.gov/). We found that signalling entropy was
significantly lower in lung adenocarcinoma patients who were alive at last follow up as opposed
to those who had died (p < 0.03). Fitting Cox proportional hazard models to 3 year censored
data revealed that an increased signalling entropy implied a worse prognosis in lung adenocar-
cinoma (c-index = 0.6, p < 0.007). We again separated patients into tertiles of the signalling en-
tropy distribution and found that high signalling entropy conferred almost a doubling of the
hazard rate, as assessed over the first 3 years following diagnosis (HR = 1.9, p < 0.02).
Signalling entropy was found to be associated with tumour stage, grade and smoking status,
in both TCGA and Director’s Challenge data sets, yet importantly the prognostic power of sig-
nalling entropy was independent of these clinical variables (S1 Text, S5 Fig & S6 Fig). It is of
particular note that signalling entropy is significantly prognostic if computed from either
Intra-Tumour Entropy Determines Survival in Epithelial Cancer
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004115 March 20, 2015 6 / 23Fig 2. Prognostic implications of signalling entropy in breast cancer. A) The plots display the concordance index for signalling entropy in each data
set alongside its 95% confidence interval. The overall concordance index was derived via meta-analysis using a random effects model. The vertical line
denotes concordance index = 0.5, data sets where the confidence interval for the concordance index crosses this line did not reach significance. Meta-
analysis of signalling entropy across 10 breast cancer data sets reveals that our measure is significantly prognostic across both ER positive and ER negative
subtypes. Meta-analysis across 7 breast cancer data sets reveals that our measure is also significantly prognostic within the grade 2 stratum. B) The plots
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which is not masked by experimental technique.
To validate the prognostic power of signalling entropy in lung adenocarcinoma, we per-
formed a meta-analysis across 4 further independent data sets consisting of a total of 522 lung
adenocarcinomas (S2 Table)[ 43–46]. This revealed that signalling entropy is prognostic across
all samples and across stage I samples (all samples: c-index = 0.58, 95% CI = (0.55, 0.60), p =
1.9e − 6, stage I: c-index = 0.56, 95% CI = (0.52, 0.60), p = 0.037, Fig. 3A).
Early stage lung adenocarcinoma suffers from a high relapse rate and it is important to es-
tablish more robust prognostic assessments in the stage I subgroup for chemotherapeutic treat-
ment stratification [22]. Sub-staging by size is currently the standard clinical approach to
stratify stage I tumours, however, on meta-analysis we found that this stratification, unlike sig-
nalling entropy was not significantly prognostic over the stage I stratum (Fig. 3B).
Signalling entropy’s prognostic power in breast cancer can be
represented by a small number of genes
Signalling entropy is a clear prognostic indicator in breast cancer, yet its computation requires
the expression of many thousands of genes, something which is currently cumbersome and ex-
pensive for clinical application. Moreover, our measure associates with tumour grade and ER
status in breast cancer and thus the factors driving its prognostic power independently of these
variables is unclear. We posited that the prognostic power of our measure, independent of ER
status and grade may be captured by the expression of a small number of genes, analogously to
the way the prognostic power of tumour grade was captured by the expression of the 97 gene
Sotiriou et al. signature [31].
To identify suitable genes representative of signalling entropy’s prognostic power, we first
investigated prognostic genes, which were correlated or anti-correlated with signalling entropy
independently of grade and ER status, and whose prognostic power was also independent of
grade and ER status. We then refined this gene set by fitting a Cox proportional hazards model
on 5 year censored data using all the identified genes as covariates and deleting genes which
were not significantly prognostic independently of others in the gene set. This resulted in a
small set of 81 genes, 10 of which were negatively correlated with signalling entropy and 71 of
which were positively correlated S2 Table. A Signalling Entropy prognostic score (SE score)
was then defined as the t-statistic evaluating the hypothesis that the 71 positively correlated
genes are expressed more highly than the 10 negatively correlated genes (after z-score normal-
ising the data).
By using signalling entropy to refine a set of prognostic genes identified by Cox regression,
our approach refines the feature selection approach based on correlation with outcome [24].
Consequently, the genes utilised to construct our SE score are both correlated with outcome
and with signalling entropy and thus should provide a prognostic indicator representative of
signalling promiscuity. Criticism of feature selection for prognostic classifiers based on gene
sets ranked by correlation with outcome has stemmed from the considerable discordance of
such features between data sets [47, 48]. By using signalling entropy to refine the prognostic
gene set we found that this gene set instability was reduced. The genes which were both
display the negative of the log10 of the p-value for a survival analysis using Cox-regression on 5-year censored data, evaluating the prognostic significance of
signalling entropy and MammaPrint in each data set. The overall p-value was produced by a Fisher’s combined test. The vertical red line on each plot
denotes p = 0.05; data sets in which the bar crosses this line reached significance for the corresponding score. Meta-analysis comparison of signalling
entropy with MammaPrint across 10 breast cancer data sets, demonstrates that only signalling entropy is significantly prognostic across ER
negative samples.
doi:10.1371/journal.pcbi.1004115.g002
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PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004115 March 20, 2015 8 / 23Fig 3. Prognostic implications of signalling entropy in lung adenocarcinoma. A) The plots display the concordance index for signalling entropy in each
data set alongside its 95% confidence interval. The overall concordance index was derived via meta-analysis using a random effects model. The vertical line
denotes concordance index = 0.5, data sets where the confidence interval for the concordance index crosses this line did not reach significance. Meta-
analysis of signalling entropy across 7 lung adenocarcinoma data sets reveals that our measure is significantly prognostic across all samples and within the
stage I stratum. B) The plots display the negative of the log10 of the p-value for a survival analysis using Cox-regression on 3-year censored data, evaluating
Intra-Tumour Entropy Determines Survival in Epithelial Cancer
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ery and validation sets of METABRIC as compared to the genes which were only prognostic.
Moreover, this increase in overlap was significantly higher than would be expected by chance
(p < 10e − 5, based on re-sampling size matched sets of prognostic genes and assessing over-
lap). To further confirm this increased rodustness, we derived a set of genes for constructing an
SE score from the METABRIC validation set, using an identical procedure to that performed
on the discovery set. This gene list was slightly shorter than for the discovery set (55 genes, 34
positively correlated and 13 negatively correlated with signalling entropy) but had an overlap
of 4 genes, significantly more than would be expected by chance (p = 0.012, based on re-sam-
pling size matched sets of prognostic genes and assessing overlap). We provide the lists of prog-
nostic genes both correlated and uncorrelated with signalling entropy as well as the validation
set derived SE score genes in S3 Table.
Meta-analysis across 9 independent breast cancer data sets revealed that like signalling en-
tropy, the SE score is prognostic across both ER positive and ER negative samples (ER positive:
c-index = 0.63, 95% CI = (0.59, 0.67), p = 4.6e − 15, ER negative: c-index = 0.62, 95% CI =
(0.58, 0.66), p = 8.1e − 8, Fig. 4A). Moreover, meta-analysis further demonstrated that the SE
score performed comparably to MammaPrint over ER positive samples (SE score vs Mamma-
Print: p = 0.18, Fig. 4B), and out-performed MammaPrint over ER negative samples (SE score
vs MammaPrint: p = 0.04, Fig. 4C). Whence the prognostic power of our measure is well cap-
tured by the expression of this small set of genes.
A signalling entropy derived prognostic score outperforms microarray
based prognostic indicators in lung adenocarcinoma
We next investigated whether a similar SE score could be computed for lung adenocarcinoma.
Signalling entropy is correlated with, yet prognostically independent of tumour stage in lung
adenocarcinoma, we therefore aimed to derive a score that represented the prognostic power of
our measure independently of tumour stage. To achieve this we considered the Director’s Chal-
lenge data set of 398 lung adenocarcinomas as a discovery set [42]. We performed an analogous
procedure as described above for breast cancer to identify genes associated with signalling
entropy’s prognostic power independently of tumour stage in lung cancer, with the only differ-
ences being that we adjusted for tumour stage, rather than ER status and grade, and used 3 year
censored data rather than 5 year. This resulted in a small set of 29 genes, 8 of which were nega-
tively correlated with signalling entropy and 21 of which were positively correlated (S4 Table).
An SE score was then defined again as the t-statistic evaluating the hypothesis that the positive-
ly correlated genes are expressed more highly than the negative.
Meta-analysis across 5 independent validation data sets revealed that the SE score is prog-
nostic across all samples and across stage I samples (all samples: c-index = 0.62, 95% CI =
(0.59, 0.66), p = 1.9e − 11, stage I: c-index = 0.66, 95% CI = (0.60, 0.71), p = 3.35e − 5, Fig. 5A).
We next compared our SE score to a leading gene expression based prognostic indicator for
lung adenocarcinoma, the expression of the gene CADM1, which was recently found to be a su-
perior prognostic indicator to many others in the literature [44]. CADM1 expression
the prognostic significance of signalling entropy and tumour stage in each data set. The overall p-value was produced by a Fisher’s combined test. The
vertical red line on each plot denotes p = 0.05; data sets in which the bar crosses this line reached significance for the corresponding score. Meta-analysis
comparison of signalling entropy with pathological tumour stage across 7 lung adenocarcinoma data sets, demonstrates that signalling entropy outperforms
the stage Ia/b sub staging across stage I samples.
doi:10.1371/journal.pcbi.1004115.g003
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pathological tumour stage (CADM1 expression vs stage: p = 0.03). In contrast the SE score per-
formed comparably to tumour stage (SE score vs stage: p = 0.13, Fig. 5B).
Conventional tumour sub staging by size within the stage I stratum, is established clinical
practice, it has thus been suggested that prognostic scores should aim to provide information
which complements this staging, rather than seeks to replace it [49]. We therefore evaluated
whether prognostic models which combined either the SE score or CADM1 expression with
stage Ia/b status within the stage I sub group, outperformed stage Ia/b status alone. We found
Fig 4. Meta-analysis comparison of the breast cancer SE score with MammaPrint. A) Survival analysis statistics for the SE score and MammaPrint over
ER positive samples and ER negative samples separately, c-index denotes concordance index and p denotes p-value. B) & C) The plots display the
concordance index for the SE score and MammaPrint in each data set alongside 95% confidence intervals. The overall concordance indices were derived
and compared via meta-analysis using a random effects model. The vertical line denotes concordance index = 0.5, data sets where the confidence interval
for the concordance index crosses this line did not reach significance. Meta-analysis reveals that the SE score performs comparably to MammaPrint in ER
positive samples (B) and outperforms MammaPrint across ER negative samples (C).
doi:10.1371/journal.pcbi.1004115.g004
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nocarcinomas (SE score+stage vs stage: p = 0.025), whereas CADM1 expression made no im-
provement over stage Ia/b (CADM1 expression+stage vs stage: p = 0.13, Fig. 5C). Whence it
may be argued that the SE score provides a stronger candidate prognostic tool than CADM1
expression for clinical application.
Another popular prognostic score for lung adenocarcinoma was derived recently by Kratz
et al.[ 22], similarly to OncotypeDX however, this score is based on RT-PCR and thus a direct
comparison is difficult. However, a microarray based approximation of the Kratz et al. score
was found to perform comparably to signalling entropy both across all samples (SE score vs
Kratz et al. score: p = 0.21) and across stage I samples (SE score vs Kratz et al. score: p = 0.37,
S7 Fig).
Fig 5. Meta-analysis comparison of the lung cancer SE score with the expression of CADM1. A) Survival analysis statistics for the SE score and
CADM1 expression over all samples and stage I samples, statistics across stage I samples are provided for the 2 scores combined with stage Ia/b status, c-
index denotes concordance index and p denotes p-value. B) The plots display the concordance index for the SE score, CADM1 expression and pathological
tumour stage in each data set alongside 95% confidence intervals. The overall concordance indices were derived and compared via meta-analysis using a
random effects model. The vertical line denotes concordance index = 0.5, data sets where the confidence interval for the concordance index crosses this line
did not reach significance. Meta-analysis across 5 validation data sets reveals that the SE score performs comparably to tumour stage, whilst CADM1
expression is outperformed by tumour stage. (C) The plots display the concordance index for the SE score and CADM1 expression combined with stage Ia/b
status, as well as stage Ia/b status alone, for stage I samples in each data set alongside 95% confidence intervals. Meta-analysis across 5 validation data
sets reveals that only the SE score adds prognostic value to stage Ia/b status.
doi:10.1371/journal.pcbi.1004115.g005
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involved in cancer stem cells and treatment resistance
Given the power of signalling entropy as a prognostic factor in both breast and lung cancer we
next investigated which genes and pathways were associated with signalling entropy’s prognos-
tic impact, independently of other clinical variables.
To determine which gene sets were enriched among the genes prognostically related to sig-
nalling entropy independently of other variables, we considered for breast cancer a list of 320
genes which were prognostic, independent of ER status and grade, and correlated with signal-
ling entropy, again independently of ER status and grade, in both MEATBRIC datasets. For
lung adenocarcinoma we considered a list of 158 genes identified as prognostic independently
of stage, and correlated with signalling entropy, again independently of stage, in both the Di-
rector’s Challenge and TCGA data sets. The two gene lists displayed an overlap of 47 genes (S5
Table displays both gene lists). We performed a gene set enrichment analysis, using a Fisher’s
Exact test, comparing each of these gene lists separately against the Molecular Signatures
Database [50]( S6 Table shows the top 10 enriched gene sets for both gene lists). The decision
to use these gene sets for the enrichment screens, rather than the genes utilised to derive
the SE scores was due to them being derived from multiple data sets and thus more robustly
representative of signalling entropy’s prognostic associations. We note that gene set enrich-
ment analysis performed on the genes comprising the SE scores gave broadly similar results
(S7 Table).
The genes found to prognostically associate with signalling entropy in both lung and breast
cancer showed considerable concordance in enrichment profiles (even after removal of the 47
genes in the overlap S6 Table). The strongest enrichment was for genes associated with poor
survival in lung cancer, histological grade in breast cancer and cell proliferation, supporting the
notion that signalling entropy is a prognostic measure of cell anaplasia. In addition, consider-
able enrichment was found for genes down regulated by the therapeutic agent salirasib and by
EGFR inhibitors, as well as for genes as up regulated in cell lines resistant to the chemothera-
peutic doxorubicin, supporting the hypothesis that signalling entropy associates with
therapeutic resistance.
Enrichment was also found for gene sets associated with stem cells and certain CSC path-
ways. Examples include, genes down-regulated by EZH2, a well known stem cell gene involved
in the pathogenesis of several cancers and which plays a documented role in both breast and
lung CSCs [51–54]. The set of genes down regulated by CTNNB1 knock-out, a critical compo-
nent of the Wnt signalling pathway, posited to be important in CSCs and their therapeutic re-
sistance [55] were also enriched. Targets of BMP2 were among the most enriched gene sets in
breast but not lung cancer, which is intriguing given the role of this gene specifically in breast
CSCs [56]. Enrichment was also found for many gene sets associated with immune
system processes.
Thus signalling entropy is prognostically related to genes associated with both CSCs and
treatment resistance, across multiple malignancies and independently of clinical variables. This
result confirms our initial postulate that signalling entropy is a powerful prognostic measure,
related both to cell anaplasia and CSCs as well as treatment resistance.
Discussion
The discovery that CSCs show resistance to conventional therapy necessitates an evaluation of
their prognostic and predictive value, as well as the development of targeted therapies [8, 9].
The notion of tumour cell plasticity raises further challenges [57] with recent discoveries sug-
gesting that CSCs may arise from the tumour bulk by simple changes [58]. This calls into
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picture of cancer cells as malleable entities capable of generating considerable heterogeneity.
Recent observations have also demonstrated the importance of characterising such intra-tu-
mour heterogeneity in the prognostic assessment of epithelial cancers [17]. The measurement
of both CSC abundance and intra-tumour heterogeneity in a clinically relevant manner, how-
ever, presents a challenge [59]. The majority of currently suggested approaches are limited in
sample size, and require the time consuming collection of large new data sets (such as multiple
biopsies from single tumours) for validation and proof of concept.
Here we have shown that signalling entropy, a measure of pathway promiscuity, which is el-
evated in CSCs as compared to the tumour bulk is also a potential correlate of intra-tumour
heterogeneity. Importantly, our measure is applicable to the plethora of publicly available bulk
tumour, genome wide expression data, facilitating swift validation of its prognostic impact on
large data sets. By considering 5360 primary tumour samples, we have demonstrated that our
measure is a powerful prognostic indicator in both breast and lung cancer. In breast cancer our
measure is prognostic within the grade 2 stratum and both ER positive and negative subtypes.
In lung adenocarcinoma, our measure is prognostic within the stage I stratum, out-performing
tumour size.
Signalling entropy is computed from the expression of many thousands of genes and thus is
not swiftly translatable. Moreover, it is associated with yet prognostically independent of a
number of clinical variables in both breast and lung cancer. We thus used feature selection to
derive a small set of genes which capture the prognostic power of signalling entropy indepen-
dently of other clinical variables, thus representing a more readily applicable quantifier of stem-
ness and intra-tumour heterogeneity.
Expression based prognostic indicators for epithelial cancers have been a topic of consider-
able interest in recent years [22–25, 44, 60]. Arguably the most successful application has been
to breast cancer, where OncotypeDX and MammaPrint are currently in clinical trials for guid-
ing the management of ER positive breast cancer [26, 27]. Though powerful, these assays are
limited to the ER positive subtype and importantly ignore CSC abundance and intra-tumour
heterogeneity. There also exist many more sophisticated prognostic signatures for breast can-
cer, derived from within the DREAM challenge consortium, and several of which have demon-
strated improvement over MammaPrint or OncotypeDX [61–64]. The aim of our work, was
first to introduce a prognostic measure of signalling promiscuity, which by approximating CSC
abundance and intra-tumour heterogeneity may prove a basis by which to improve the con-
struction of prognostic models for epithelial cancers, and secondly, to
compare it to clinically well established or validated signatures such as MammaPrint and
OncotypeDX. A direct comparison of signalling entropy to the prognostic indicators from
the DREAM challenge, which have not yet entered the clinical setting, is beyond the scope of
this work.
In comparing signalling entropy to signatures such as MammaPrint it is worth pointing out
that a direct comparison is unfair signalling entropy does not involve feature selection. Even
so, signalling entropy was found to be more robust than MammaPrint across ER+ and ER-
breast cancer. Although signalling entropy was not found to outperform existing prognostic
markers in lung adenocarcinoma, by using the SE score, derived by signalling entropy guided
feature selection, it was possible to outperform existing state of the art prognostic factors such
as CADM1 expression across independent data sets.
The nature of signalling entropy as a measure of pathway promiscuity, which correlates
with CSCs and associates with intra-tumour heterogeneity [8, 9], led us to postulate that it may
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sponse. Here we demonstrated that signalling entropy’s prognostic power in epithelial cancers
is indeed related to both treatment resistance and CSC pathways.
We thus propose signalling entropy as a powerful and readily applicable tool for assessing
the prognostic impact of signalling promiscuity across multiple epithelial cancers. In addition
to being a strong prognostic factor which outperforms the leading expression based indicators,
our measure may also provide insights into intra-tumour heterogeneity, treatment resistance
and CSC mechanisms.
Materials and Methods
Details of data sets used, the interaction network and all statistical methods can be found in the
S1 Text.
Signalling Entropy
Signalling entropy was computed in a sample specific manner as described in [16]. Briefly,
each sample is first integrated with a Protein Interaction Network (PIN) (see S1 Text) to create
a sample specific stochastic matrix, P =( pij). By integrating each sample with the PIN, rather
than considering a complete network in which every protein pair can directly interact, we bene-
fit both from a reduction in computational complexity and an improved biological relevance
from a focus on direct interactions. Integration with the PIN filters out indirect interactions
even if strong correlations are present, making our analysis robust to confounding effects. By
using each sample to weigh the PIN we are also reducing the noise present in the network by
providing it with a sample-specific biological context. The i
th row of P defines a probability dis-
tribution describing the rates of reaction of protein i with each of its neighbours in the PIN.
These distributions are constructed by appealing to a simplified version of the mass action
principle, namely that the rate of a reaction is proportional to the product of the active masses
of the reagents involved. We assume that log normalised gene expression is a rough proxy for
protein concentration and thus compute P as follows:
pij ¼
Ej=
P
k2NðiÞEk; if j 2 NðiÞ
0; else
(
ð1Þ
where Ej is the log-normalised expression of gene j in the given sample and N(i) denotes the set
of direct interaction partners (neighbours) of gene i in the PIN. We note that from this deﬁni-
tion ∑j pij = 1 for all j, i.e., P is row stochastic, and the i
th row corresponds to the weighted inter-
action distribution of protein i in the given sample. We note that not all proteins in the PIN
have a corresponding probe in the microarray or sequence in the RNA-seq data, consequential-
ly the PIN we consider is the maximally connected component of the original PIN after the re-
moval of missing proteins.
For each protein i we then define the local entropy of its interaction distribution, Si, which
quantifies the promiscuity of its signalling within the sample:
Si ¼ 
X
j2NðiÞ
pij logpij: ð2Þ
Signalling entropy is a global measure of signalling promiscuity in a given sample and thus
is computed from the entire stochastic matrix pij as the entropy rate, ~ SR, of the stochastic
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~ SR ¼
X
i
piSi; ð3Þ
where πi denotes the stationary distribution of the stochastic matrix, satisfying ∑i πi pij = πj.W e
note that πi is therefore the non-degenerate eigenvector of P corresponding to the eigenvalue 1
and that by the Perron Frobenius theorem, the existence of πi requires that the matrix P be
irreducible; this is guaranteed by the fact that the PIN considered is connected and non-
bipartite [65].
The maximum entropy rate of a weighted network, MR, depends solely upon its adjacency
matrix, A =( Aij), and can be calculated as the entropy rate of the stochastic matrix pij = Aij νj/
λνi, where λ and ν are the dominant eigenvalue and corresponding eigenvector of A, respective-
ly [66]. In order to ensure the results presented in this paper are comparable with those of pre-
vious studies on signalling entropy, we will present our findings in terms of normalised
signalling entropy:
SR ¼ ~ SR=MR: ð4Þ
A closed form expression for signalling entropy is derived and analysed in the S1 Text.
R-scripts for the computation of signalling entropy are freely available for download at www.
sourceforge.net/projects/signalentropy.
Super-additivity and heterogeneity
We hypothesised that the signalling entropy of a heterogeneous sample generated from a
50:50 mixture of two homogeneous cell types will be greater, on average, than the signalling
entropy of a homogeneous sample. Here we show that if signalling entropy is super-additive
then the hypothesis is correct. Let us first define some preliminaries: Let xi 2 R
> 0 be the
expression of gene i in cell type X, and denote the vector containing all such variables by
x ¼ð xiÞ
n
i¼1 2 O   R
>0, where O is some bounded domain. In our analysis x will represent the
vector of log normalised gene expression values for a homogeneous sample, we note that as the
expression of genes cannot be infinite we bound x within a finite domain O, of biologically ad-
missible expression regimes.
Our hypothesis on signalling entropy thus amounts to proving the following proposition:
Proposition. Let x, y 2 O, then
Z
O
Z
O
SR
x þ y
2
  
  SRðxÞ
  
dxdy > 0: ð5Þ
Let us consider a the following claim:
Claim (Super-additivity). Let x, y 2 O then
SR
x þ y
2
  
>
SRðxÞ
2
þ
SRðyÞ
2
: ð6Þ
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claim is true then as it is a strict bound 9 >0 such that SR
xþy
2
  
>
SRðxÞ
2 þ
SRðyÞ
2 þ  . Whence
Z
O
Z
O
SR
x þ y
2
  
  SRðxÞ
  
dxdy >
Z
O
Z
O
SRðyÞ
2
 
SRðxÞ
2
þ  
  
dxdy ð7Þ
¼j Oj
2  ð8Þ
> 0; ð9Þ
and thus the proposition is true.
Thus if signalling entropy is super-additive over homogeneous cell types, this implies that
signalling entropy will on average be elevated in heterogeneous mixtures of cell types. These
propositions are examined in detail in S1 Text.
Supporting Information
S1 Text. This document contains supplementary materials and methods and supplementa-
ry results to complement the manuscript.
(PDF)
S1 Table. GEO and ArrayExpress accession numbers for the breast cancer and lung adeno-
carcinoma data sets. Sample counts are provided for ER segregated and grade 2 samples in the
case of breast cancer, and also for stage I samples in the case of lung adenocarcinoma.
(XLSX)
S2 Table. The genes utilised to construct the signalling entropy prognostic score in breast
cancer, derived from the METABRIC discovery set. Genes are separated into those found to
positively correlate with signalling entropy and those negatively correlated.
(XLSX)
S3 Table. The genes utilised to construct the signalling entropy prognostic score derived
from the METABRIC validation set. Genes are separated into those found to positively
correlate with signalling entropy and those negatively correlated, the genes which overlap with
the discovery set derived set are highlighted in yellow. Also presented are genes which are
prognostic independently of ER status and grade in both discovery and validation sets of
METABRIC (middle table). Genes which are both prognostic and correlated with signalling
entropy, independently of ER status and grade, in both discovery and validation sets of
METABRIC are presented as the rightmost table.
(XLSX)
S4 Table. The genes utilised to construct the signalling entropy prognostic score in lung
adenocarcinoma. Genes are separated into those found to positively correlate with signalling
entropy and those negatively correlated.
(XLSX)
S5 Table. Genes utilised in the gene set enrichment analysis to identify gene sets associated
with signalling entropy’s prognostic power in breast and lung cancer. In the case of breast
cancer these are prognostic genes which correlate with signalling independently of ER status
and grade and whose prognostic power is also independent of these variables, in both METAB-
RIC data sets. In the case of lung cancer, these are prognostic genes which are correlated with
signalling entropy independently of tumour stage and whose prognostic power is also
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sets. Genes are separated into those found to positively correlate with signalling entropy and
those negatively correlated.
(XLSX)
S6 Table. Gene set enrichment analysis results displaying the top 10 most significant en-
riched gene sets associated with signalling entropy’s prognostic power in breast and lung
cancer. Tables display results for the gene set enrichment analysis performed on gene lists
identified in lung and breast cancer separately, both with and without the intersection of the
two lists removed.
(XLSX)
S7 Table. Gene set enrichment analysis results displaying the top 10 most significant en-
riched gene sets associated with the genes utilised to construct the SE score in both breast
cancer and lung adenocarcinoma.
(XLSX)
S1 Fig. Signalling entropy is correlated with both the Ben-Porath et al. and Sotiriou et al.
tumour grade signatures. The p-values denote the significance of the Pearson
correlation coefficient.
(EPS)
S2 Fig. Signalling entropy outperforms the Ben-Porath ES cell signature in measuring
tumour grade. A) Signalling entropy is associated with histological tumour grade. B) Unlike
signalling entropy the Ben-Porath et al. signature cannot discriminate between grade 1 and
grade 2 breast cancers in the METABRIC discovery data set. All p-values are derived from
Wilcoxon tests.
(EPS)
S3 Fig. Prognostic associations of random gene expression signatures in METABRIC.
A) Kaplan-Meyer plots for 5 year censored survival data are presented for each of the 3 random
gene expression signatures described by Venet et al. in each METABRIC data set, p-values de-
note the significance of a Cox-regression for each random signature as assessed by a Wald-test.
We see that only KRISHNAN2007DEFEAT is significantly prognostic in both METABRIC
datasets. B) Kaplan-Meyer plots for 5 year censored survival data are presented for each of the
KRISHNAN2007DEFEAT expression signature in each METABRIC data set, divided into
ER+ and ER- samples, p values denote the significance of a Cox-regression for each random
signature as assessed by a Wald-test. We see that the random signature is not prognostic within
ER subtypes.
(EPS)
S4 Fig. Meta-analysis comparison of signalling entropy with OncotypeDX. The plots display
the concordance indices for signalling entropy and a microarray based approximation of
OncotypeDX in each data set alongside 95% confidence intervals. The overall concordance in-
dices were derived via meta-analysis using a random effects model. The vertical line denotes
concordance index = 0.5, data sets where the confidence interval for the concordance index
crosses this line did not reach significance. Meta-analysis across 10 data sets reveals that signal-
ling entropy performs comparably to OncotypeDX across (A) ER positive samples and (B) ER
negative samples.
(EPS)
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PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004115 March 20, 2015 18 / 23S5 Fig. Signalling entropy is associated with the level of tumour differentiation in lung ade-
nocarcinoma in the Director’s Challenge dataset. A) Signalling entropy is correlated with the
Ben-Porath et al. tumour grade signature, the p-value denotes the significance of the Pearson
correlation coefficient. B) Signalling entropy is associated with histological tumour grade, p-
values are derived from Wilcoxon tests.
(EPS)
S6 Fig. Signalling entropy is elevated in lung adenocarcinoma patients with a history of
smoking. p-values are derived from Wilcoxon tests.
(EPS)
S7 Fig. Meta-analysis comparison of signalling entropy with the score of Kratz et al. A) The
plots display the concordance indices for signalling entropy and a microarray based approxi-
mation of the Kratz et al. score in each data set alongside 95% confidence intervals. The overall
concordance indices were derived via meta-analysis using a random effects model. The vertical
line denotes concordance index = 0.5, data sets where the confidence interval for the concor-
dance index crosses this line did not reach significance. Meta-analysis across 6 data sets reveals
that signalling entropy performs comparably to the Kratz et al. score across all samples. (B)
The plots display the concordance indices for signalling entropy and the Kratz et al. score
combined with stage Ia/b status for stage I samples in each data set alongside its 95% confi-
dence interval. Meta-analysis across 6 data sets reveals that signalling entropy performs compa-
rably to the score of Kratz et al..
(EPS)
S8 Fig. Analysis of the expression sign(1 − 1/b +2 / a)+sign(1 − a +2 b), which evaluates to 2
if signalling entropy is super-additive and is derived in the S1 Text, for a range of biologi-
cally plausible values of a and b, parameters derived in the S1 Text. A) Histogram of values
of the sign(1 − 1/b +2 / a)+sign(1 − a +2 b) evaluated over 2000 equally incremented values of
a and b over the range a, b 2 [0.01, 20].
We see that the majority of the values satisfy the condition sign(1 − 1/b +2 / a)+sign(1 − a +
2b) = 2. B) Plot of sign(1 − 1/b +2 / a)+sign(1 − a +2 b) for a, b 2 [0.01, 20], values of a are plot-
ted on the x axis whilst colors from red to green to blue denote increasing values of b, we see
that as a and b increase the expression quickly evaluates to 2.
(EPS)
S9 Fig. Demonstration that the claim SR
xþy
2
  
>
SRðxÞ
2 þ
SRðyÞ
2 is correct for all pairwise combi-
nations of samples in GSE2361.
(EPS)
S10 Fig. Signalling entropy of homogeneous and mixed tissues. The first box represents the
signalling entropy distribution of 33 unmixed tissues, whilst each subsequent labelled box rep-
resents the signalling entropy distribution of the labelled tissue mixed with each of the remain-
ing 32 tissues. The red line represents the median of the unmixed samples. We see that for 20/
33 tissue types, the median of the mixture is greater than the median of the pure samples, sug-
gesting that on average the signalling entropy of the mixture is greater than the signalling en-
tropy of the pure sample.
(EPS)
S11 Fig. Demonstration that the claim, ∫Ω∫Ω SR
xþy
2
  
−SRðxÞ
  
dxdy > 0 is correct for samples
in GSE2361. The p-value is for a paired Wilcoxon test.
(EPS)
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